Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | ACHE | P22303 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | TNF | P01375 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358934 | 0.99 | PDE4A (0.69) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL10346588 | 0.96 | PDE4A (0.68) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL10346583 | 0.95 | PDE4A (0.64) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL7030926 | 0.94 | PDE4A (0.62) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL10346307 | 0.94 | LMNA (0.61) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL19601304 | 0.92 | PDE4A (0.58) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL7360054 | 0.90 | PDE4A (0.56) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL10346304 | 0.89 | LMNA (0.56) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL3847240 | 0.89 | PDE4A (0.55) | PDE4ALMNACYP1A2NFKB1ACHE | |
| SCHEMBL8484463 | 0.88 | PDE4A (0.64) | PDE4ALMNACYP1A2NFKB1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| EP-0821960-B1 | Use of xanthine derivatives combined with a 5-substituted-isoxazole-4-carboxamide derivative and/or a 2-cyano-3-hydroxycrotonamide derivative for the modulation of apoptosis | HOECHST AG (DE) | 2003-04-09 | — | — | EP | claimed |
| US-6432968-B1 | IMMUNOSUPPRESSANTS FOR PATIENTS WITH CANCER, AUTOIMMUNE DISEASES, AND VIRAL INFECTIONS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-13 | — | — | US | claimed |
| US-5981536-A | INHIBITING THE DEPHOSPHORYLATION OF COFILIN AND THUS HAVING MODULATING INFLUENCE ON APOPTOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | claimed |
| US-5958413-A | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor | CELLTECH LIMITED (DE) | 1999-09-28 | — | — | US | claimed |
| US-5856330-A | MODULATION OF APOPTOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | claimed |
| US-5795574-A | COSMETICS WITH SUBSTANCE P ANTAGONIST | SOCIETE L'OREAL S.A. (FR) | 1998-08-18 | — | — | US | claimed |
| EP-0821960-A1 | Use of xanthine derivatives for the modulation of apoptosis | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-04 | — | — | EP | claimed |
| EP-0797448-A2 | COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-01 | — | — | EP | claimed |
| US-5641773-A | ADMINISTERING COMBINATION OF TAT INHIBITOR AND NF-KB INHIBITOR | DANA-FARBER CANCER INSTITUTE (US) | 1997-06-24 | — | — | US | claimed |
| EP-0564461-B1 | THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR | CELLTECH THERAPEUTICS LTD (GB) | 1997-01-02 | — | — | EP | claimed |
| WO-1996005854-A2 | COMBINATION PREPARATION, CONTAINING CYCLOSPORIN A OR FK506 OR RAPAMYCIN AND A XANTHINE DERIVATIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-29 | — | — | WO | claimed |
| US-5350753-A | Treatment of bacterial infectious diseases and septic shock | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-27 | — | — | US | claimed |
| US-20240115657-A1 | COMPOSITION COMPRISING OIL DROPS | Sublimity Therapeutics Limited (IE) | 2024-04-11 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20160193213-A1 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES | HARROW IP, LLC | 2016-07-07 | — | — | US | disclosed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193213-A1 | PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES | XDH, PNPO, PNP | PDE4A 19/4885LMNA 586/4885CYP1A2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.